Introduction
Beta-thalassemia is the most common autosomal recessive single-gene disorder in the world (1) . According to the World Health Organization, abnormal hemoglobin frequency is at 7% globally (2) . Mutations in the HBB gene lead to diseases such as sickle cell anemia, β-thalassemia, and other abnormal hemoglobins. To date, approximately 200 different mutations have been reported in the β-globin gene (3) .
Although the Turkish population has a reported prevalence of 2.1%, these mutations are as high as 13% in other regions (4) (5) (6) . In Turkey, more than 35 different β-thalassemia-causing mutations have been described by molecular analysis (7, 8) . Most commonly, β-globin gene mutations are observed in the Turkish population, including IVSI-110 (G>A) (40.88%), IVSI-6 (10.3%), IVSII-1 (8.1%), IVSII-745 (6.2%), IVSI-1 (5.7%), and HbS (4.9%), covering 71.18% of all β-globin gene mutations. Along with the HbS mutation, this rate increases to 76% in the Turkish population (7, 9) . Thalassemia mutation screening can be performed prenatally and postnatally. Current conventional diagnostic methods, such as erythrocyte index and morphology, Hb electrophoresis, HbA2 identification, and identification of HbH inclusion bodies in erythrocytes, provide the diagnosis, yet none can determine the mutation (10, 11) . Most of the time, patients are able to obtain an accurate diagnosis with the use of these methods, yet it is still necessary to create molecular tests for identification of carriers, silent carriers, and prenatal cases. In addition to prenatal diagnosis, using the support of clinical diagnoses with reliable laboratory results is very important for patient follow-up, prognosis, and genetic counseling (11) . Molecular methods that are currently used in the identification of thalassemia mutations include oligonucleotide hybridization, restriction endonuclease analysis, amplification refractory mutation system (ARMS), temporal temperature gradient gel electrophoresis, strip assay, LightCycler technology, and DNA sequence analysis of the β-globin gene (9, 10, (12) (13) (14) (15) .
In the past, malaria endemism in Mediterranean countries was very high. It is known that in areas with persistent malaria outbreaks, because the benign sickle trait possesses resistance to malarial infection, heterozygous individuals have a distinct advantage. This is why individuals with heterozygous alleles are far more common in these areas. Furthermore, the number of carriers related to consanguineous marriage frequency in Turkey is higher than in other countries. Considering the high fertility rates in Turkey, high pregnancy rates for carriers are to be expected. For the management of thalassemia, it is necessary to develop rapid, easily applicable, relatively inexpensive, and reliable new screening methods for the most common mutations. For simultaneous screening of multiple mutations, the real-time PCR method is a very advantageous, easy, and reliable method of testing. It is highly flexible in relation to mutation detection probe preparation. Post-PCR processes, such as electrophoresis, are not necessary.
In this study, our aim was to develop a new molecular genetic analysis kit for screening common β-thalassemia mutations and HbS, which are observed frequently in Turkey.
Materials and methods
We defined six mutations covering 76% of all β-globin mutations in Turkey, including IVSI-110 (G>A), IVSI-6 (T>C), IVSII-1 (G>A), IVSII-745 (C>G), IVSI-1 (G>A), and HbS, in order to standardize a real-time (TaqMan) PCR method.
Our control group included DNA samples from a total of 21 patients. Eighteen of these patients have a disease with already identified mutations, and three are healthy individuals. These 21 individuals were selected from the Department of Medical Biology and Genetics, Faculty of Medicine, Akdeniz University, Antalya; Medical Genetics Laboratory, Faculty of Medicine, İstanbul University, İstanbul; and Medical Genetics Laboratory, Faculty of Medicine, İnönü University, Malatya. Control DNA was used for the validation of the developed kit and as an external control for the test. Before starting the study, we performed sequence analyses for all controls, which included both affected and healthy individuals.
A total of 35 patients selected from the Ankara Provincial Health Directorate Thalassemia Diagnosis Center were found to be carriers or affected by β-thalassemia or sickle cell anemia. Their conditions were diagnosed by using hemoglobin electrophoresis and/or high-performance liquid chromatography. Moreover, 65 patients were found to be carriers or affected by β-thalassemia or sickle cell anemia by using molecular genetic methods. These patients were selected from the Medical Genetics Laboratory, Faculty of Medicine, İstanbul University, İstanbul; Medical Faculty Laboratory, Ankara University, Ankara; and Department of Medical Genetics, Adana Numune Education and Research Hospital, Adana.
Informed consent from all participants and approval from the Gazi University Local Ethics Committee (#3657) were obtained.
DNA isolation
Approximately 5 mL of venous blood samples were drawn from 35 patients and stored in EDTA tubes at 4 °C until DNA isolations were performed. DNA isolation from the blood samples was performed according to the instructions of the Axygen DNA isolation kit. Obtained genomic DNA was stored at -20 °C. The DNA samples of the 65 patients and 21 controls were obtained from the centers mentioned above.
Real-time PCR primers and probe design
We designed primers and TaqMan probes for each mutation site, including IVSI-110 (G>A), IVSI-6 (T>C), IVSII-1 (G>A), IVSII-745 (C>G), IVSI-1 (G>A), and HbS ( Table  1) . The glucose-6-phosphate dehydrogenase (GAPDH) gene was used as an internal control. The reporters and repressors shown in Table 2 were used for the probes, which were designed specifically for the mutation sites and internal control regions. Allelic discrimination was facilitated by software analysis of the fluorescence data.
Results
The results of the 100 patients studied by TaqMan realtime PCR are shown in Table 3 . Although mutation was detected in 73 of the total 100 patients, the remainder did not have any of the mutations found in our panel. The results of the 65 patients obtained from the previously mentioned centers were confirmed by the results of the laboratories that had initially conducted the tests.
We performed DNA sequencing analysis to confirm our real-time PCR results. Therefore, we selected five patients whose mutations had been described by each of our mutation panels and six patients who had no mutations. Known mutations that were not included in our panel were detected in the sequencing results of these six patients. The sequencing results of other patients were compatible with our real-time study results, confirming the accuracy of this method. All analysis results are shown in Table 4 .
Discussion
Hemoglobinopathies, which are among the most common hereditary diseases, form a group of significant health problems in Turkey. Sickle cell anemia and β-thalassemia are the most common types of hemoglobinopathies found in Turkey. β-Thalassemia is most frequently observed in Mersin (13.6%), Antalya (13%), Hatay (10.6%), and Adana (10%), all of which are located in the Mediterranean region of Turkey (16). Thalassemia is examined in premarital carrier screening programs in Turkey and is analyzed with various methods. Among these methods and especially for nonmolecular methods, confirmation is needed by use of a molecular test. Some tests can be performed with specific kits, which are used internationally, but none of the mutations are specific to any one country. Among the aforementioned methods, sequence analysis is the gold standard; however, it is both expensive and impractical. While real-time PCR can only lead to a result with a one-step process, sequence analysis involves PCR, post-PCR purification, and sequencing steps. According to the current circumstances, our calculations show that the price of sequence analysis (~295 TL), compared to the test we used, is more than twice the cost of real-time PCR (~130 TL).
In this study, we aimed to develop a new, easily applicable, and reliable screening method for commonly observed mutations in the Turkish population. This screening method will save time and expenses prior to DNA sequencing. Real-time PCR is a preferential method due to its accuracy, fast and easy applicability, and ability Table 2 . Reporters and repressors used for the probes. to provide screening of multiple mutations at once (17) . Another advantage of the real-time PCR method is its low contamination risk, because the tube covers are always closed during genotyping (18) . For this purpose, we have designed a real-time PCR kit determining five β-thalassemia mutations [IVSI-110 (G>A), IVSI-6 (T>C), IVSII-1(G>A), IVSII-745(C>G), IVSI-1(G>A)] and the HbS mutation, which causes sickle cell anemia. These six mutations were included in the test design and account for 76% of all the β-globin mutations in the Turkish population (8) . We used a housekeeping gene (GAPDH) as an internal control to make sure that we prepared adequate and appropriate conditions for amplification, as well as for understanding the DNA that was added to the tube. We used non-DNA-containing negative controls in order to determine the presence of contamination in our study. We did not observe contamination during any phase of the study and we preferred the use of TaqMan probes. Since the TaqMan probe method has relatively easy design and optimization, it can be easily used both in expression profile extraction and in allelic discrimination (19) . Optimization of our kit was performed with control DNA samples. These samples consisted of the wild-type and known mutations. In order to confirm our results, random selections from our evaluated samples were sent for DNA sequencing analysis. When comparing sequencing results to the obtained results from our real-time PCR method, we observed that all results were compatible when confirming the accuracy of our method. Some mutations identified with DNA sequence analysis were not detected with our developed kit, because they were not included in our panel (Table 4) . Rapid results are an especially important feature when defining mutations in at-risk couples that may require prenatal diagnosis. Therefore, real-time PCR is an appropriate method for the screening of couples at increased risk. Obtaining the results on the same day, or even in a few hours, and setting up PCR and the cycles in the machine are the primary advantages of this method. This study allowed us to examine the six most common β-globin mutations encountered in the Turkish population simultaneously and in a brief interval of 1-1.5 h.
In conclusion, in this study we designed a reliable β-globin screening kit that includes 76% of the mutations observed in Turkey. This kit can be used not only for β-thalassemia screening but also as a fast, simple, and inexpensive molecular diagnostic method. 
